Nantes, France, November 4, 2020 – AbolerIS Pharma, a pre-clinical stage biotech company specialized in the development of innovative immuno-modulators for the treatment of transplant rejection, graft-versus-host-disease and auto-immune diseases announced today the successful completion of a seed financing round of €2.5 million ($2.9M) from an investment consortium comprised of Newton Biocapital and Turenne Santé/Sham Innovation Santé. The funding will help develop technologies that preserve and stimulate regulatory T cells and control/eliminate effector T cells responsible of these diseases of the immune system.
“We thank Newton Biocapital and Turenne Santé/Sham Innovation Santé for their trust. This investment will help us to consolidate our products and reach Phase I clinical stage with the company’s first program to deplete effector T cells using a proprietary anti-CD45RC antibody. The funding will also help to consolidate our second program with the cytokine IL-34” said Carole Guillonneau, co-founder of AbolerIS Pharma.
“AbolerIS Pharma brings translational public research to generate new treatments for patients with unmet clinical needs in pathologies mediated by the immune system. “We aim to inhibit pathogenic immune responses in more subtle and specific ways than the existing treatments to ameliorate the health of patients. We also aim to do this through the creation of value and scientific knowledge by a talented team of people”, said Ignacio Anegon, co- founder of AbolerIS Pharma.
“Aboleris Pharma brings a wealth of robust experience in fundamental and pre-clinical research of immune tolerance, bringing closer to market novel treatment approaches for patients at risk of GHVD or those suffering from autoimmune diseases. Newton Biocapital is proud to take Aboleris Pharma into its portfolio, with the ambition to advance its monoclonal antibody program for first use in man within a few years” said Guy Heynen, CMO/CRO at Newton Biocapital.